PERSPECTA

News from every angle

← Back to headlines

Guggenheim Lifts Insmed Price Target to $230 Following Biotech Earnings Model Update

Guggenheim has raised its price target for Insmed Incorporated (INSM) to $230 after updating its earnings models for the biotech industry. This indicates a positive re-evaluation of the company's financial prospects.

24 Apr, 13:40 — 24 Apr, 13:40
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual127d ago

Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models

Read full article →

Related Stories

India Bans Two Major Brands From Selling Hing Powder

27m ago

OpenAI Terminates Partnership With Cursor Following SpaceX Acquisition

38m ago

Fed Chair Warsh signals rate hikes as inflation stays elevated

2h ago

College Dropout Turns Full-Time Pokémon Card Reseller With $7.8M in Sales

3h ago